Search
Search Results
##search.searchResults.foundPlural##
-
ADVANCES IN THE TREATMENT OF MALARIA
2846PDF: 1124HTML: 5992 -
THE SYSTEMIC MASTOCYTOSIS: RADIOLOGICAL POINT OF VIEW Systemic mastocytosis
1498PDF: 543HTML: 716 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1959PDF: 712HTML: 684Table1: patient's characteristics: 155Table 2: profile of each patient: 178 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2582PDF: 800HTML: 5214 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1463PDF: 1062HTML: 217 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3254PDF: 1709HTML: 1086 -
-
Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era Antiviral and monoclonal Antibodies in Haematological Patients in the omicron era
1289PDF: 937HTML: 91 -
CONTINUOUS CULTURES OF PLASMODIUM FALCIPARUM ESTABLISHED IN TANZANIA FROM PATIENTS WITH ACUTE MALARIA In vitro Malaria cultures
1674PDF: 539HTML: 207 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1163PDF: 917HTML: 289 -
Correlation to FVIII:C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
2226PDF: 778HTML: 857Figure 2: 213Figure 1: 167 -
Acquired Hemophilia A successfully treated with rituximab
1937PDF: 1143HTML: 1458Figure 1: 176 -
-
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology
1066PDF: 961HTML: 327 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
3889PDF: 1478HTML: 8513 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1418PDF: 902Suppl. Files: 454HTML: 236 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1725PDF: 1163HTML: 246 -
PERIPHERAL NERVOUS SYSTEM INVOLVEMENT IN LYMPHOPROLIFERATIVE DISORDERS
1758PDF: 878HTML: 375Fig1: 232Fig.2: 252Fig. 3: 182Fig. 5: 195Fig. 4: 223 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2376PDF: 997HTML: 1647Fig 1: 185Tab I: 210Cover Letter: 205 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3325PDF: 1470HTML: 4002 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
943PDF: 513HTML: 193 -
CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
1665PDF: 721HTML: 2338 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2500PDF: 923HTML: 530 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1772PDF: 1074HTML: 249 -
Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major
612PDF: 483Html: 105 -
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2325PDF: 987HTML: 7624Untitled: 276Fig2: 184Fig3: 169Fig4: 180 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1266PDF: 874HTML: 297 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
3916PDF: 1097HTML: 444 -
THE EFFECT OF ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS IN IBADAN, NIGERIA. ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS
2331PDF: 975HTML: 72







